Erythropoiesis-stimulating agents are generally the first line of treatment of anemia in lower risk myelodysplastic syndrome patients. We prospectively investigated the predictive value of somatic mutations, and biomarkers of ineffective erythropoiesis including flow cytometry RED score, serum GDF-15, and hepcidin levels. Inclusion criteria were: Erythropoiesis stimulating agents naive, IPSS low or intermediate-1 MDS with Hemoglobin level< 10g/dl, red blood cell transfusion-dependent or not. Patients received epoetin zeta 40 000 IU/week and erythroid response (IWG 2006 criteria) was assessed at week 12. Serum EPO level, iron parameters and hepcidin, flow cytometry Ogata and RED score, GDF-15, and molecular analysis by next-generation sequencing were determined at baseline. 70 patients were included. Median age was 78 years. There were 22 RCMD, 19 RCUD, 14 RARS, 4 RAEB-1, 6 CMML, 2 del 5q-, 3 unclassifiable, IPSS-R was 13 very low, 47 low, 9 intermediate and high. Twenty patients were transfusion dependent. Erythroid response was 48% and median response duration was 26 months. At baseline, non-responders had significantly higher RED score, lower hepcidin/ferritin ratio. In multivariate analysis, only RED score>4 (p=0.05) and hepcidin/ferritin2000 pg/ml and hepcidin/ferritin<9 (P=0.0008, and p=0.01, respectively). In multivariate analysis, both variables were associated with shorter response duration. Erythroid response to epoetin zeta was similar to that obtained with other erythropoiesis stimulating agents. It was correlated with higher baseline hepcidin/ferritin ratio and lower RED score.